keyword
MENU ▼
Read by QxMD icon Read
search

dutasteride

keyword
https://www.readbyqxmd.com/read/29044968/a-prospective-randomised-placebo-controlled-study-of-the-impact-of-dutasteride-tamsulosin-combination-therapy-on-sexual-function-domains-in-sexually-active-men-with-lower-urinary-tract-symptoms-luts-secondary-to-benign-prostatic-hyperplasia-bph
#1
Claus G Roehrborn, Michael J Manyak, Juan Manuel Palacios-Moreno, Timothy H Wilson, Erik Pm Roos, Javier Cambronero Santos, Dimitrios Karanastasis, Janet Plastino, Francois Giuliano, Raymond C Rosen
OBJECTIVE: To prospectively assess the impact of the fixed-dose combination of the 5-alpha reductase inhibitor (5ARI), dutasteride 0.5 mg and the alpha-1 blocker, tamsulosin 0.4 mg (DUT-TAM FDC) therapy on sexual function domain scores in sexually active males with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), using the Men's Sexual Health Questionnaire (MSHQ). PATIENTS AND METHODS: This European and Australian double-blind, placebo-controlled, parallel-group study was conducted at 51 centres...
October 16, 2017: BJU International
https://www.readbyqxmd.com/read/28982631/effect-of-the-5%C3%AE-reductase-enzyme-inhibitor-dutasteride-in-the-brain-of-intact-and-parkinsonian-mice
#2
Nadhir Litim, Marc Morissette, Donatella Caruso, Roberto C Melcangi, Thérèse Di Paolo
Dutasteride is a 5alpha-reductase inhibitor in clinical use to treat endocrine conditions. The present study investigated the neuroprotective mechanisms of action of dutasteride in intact and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mice using a low dose of MPTP not affecting motor activity modeling early stages of Parkinson's disease (PD). We hypothesized that dutasteride neuroprotection is due to altered steroids levels. Dutasteride pre-treatment prevented loss of striatal dopamine (DA) and its metabolite DOPAC...
October 2, 2017: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/28975673/influence-of-dutasteride-treatment-on-serum-hormone-levels-and-aging-male-symptoms-in-patients-with-benign-prostatic-enlargement
#3
Takahiro Maeda, Eiji Kikuchi, Masanori Hasegawa, Keiko Homma, Toshiyuki Ando, Kenjiro Suzuki, Gou Kaneko, Ryuichi Mizuno, Akira Miyajima, Mototsugu Oya
OBJECTIVES: To clarify the effects of dutasteride on serum hormone levels and aging male symptoms in patients with benign prostatic enlargement. METHODS: The present prospective study was carried out in 110 symptomatic benign prostatic enlargement patients treated with daily administration of 0.5 mg dutasteride. We analyzed serum hormonal levels and aging related symptoms using a validated Aging Male Symptom questionnaire at baseline and after 3 months of dutasteride treatment...
October 3, 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28932074/mesotherapy-with-dutasteride-in-the-treatment-of-androgenetic-alopecia
#4
David Saceda-Corralo, Ana Rita Rodrigues-Barata, Sergio Vañó-Galván, Pedro Jaén-Olasolo
No abstract text is available yet for this article.
July 2017: International Journal of Trichology
https://www.readbyqxmd.com/read/28905745/re-rates-of-prostate-surgery-and-acute-urinary-retention-for-benign-prostatic-hyperplasia-in-men-treated-with-dutasteride-or-finasteride
#5
Steven A Kaplan
No abstract text is available yet for this article.
October 2017: Journal of Urology
https://www.readbyqxmd.com/read/28870861/sleep-problems-are-associated-with-development-and-progression-of-lower-urinary-tract-symptoms-luts-results-from-reduce
#6
Brandee L Branche, Lauren E Howard, Daniel M Moreira, Claus Roehrborn, Ramiro Castro-Santamaria, Gerald L Andriole, Martin L Hopp, Stephen J Freedland
INTRODUCTION: Though LUTS and sleep problems often co-occur, whether sleep disturbances are linked with LUTS development and progression is unknown. We examined the relationship between sleep problems measured by the Medical Outcomes Study Sleep Scale (MOS-Sleep) 6-item survey and LUTS development and progression in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. METHODS: REDUCE was a randomized trial testing prostate cancer chemoprevention with dustasteride in men with PSA 2...
September 1, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28817871/re-a-prospective-longitudinal-survey-of-erectile-function-status-in-symptomatic-benign-prostatic-hyperplasia-patients-treated-with-dutasteride
#7
Steven A Kaplan
No abstract text is available yet for this article.
September 2017: Journal of Urology
https://www.readbyqxmd.com/read/28800206/relative-bioavailability-of-fixed-dose-combinations-of-tamsulosin-and-dutasteride-results-from-2-randomized-trials-in-healthy-male-volunteers
#8
Olivia Burns, John Zhu, Michael J Manyak, Ramiya Ravindranath, Fariba Koosha, Nazneen Haque, Sally Chung
The relative bioavailabilities of dutasteride/tamsulosin hydrochloride 0.5 mg/0.2 mg fixed-dose combination (FDC) capsules compared with coadministered reference products (1 dutasteride 0.5-mg capsule [Avodart(®) ] + 1 tamsulosin hydrochloride 0.2-mg orally disintegrating tablet [Harnal D(®) ]) were investigated in 2 clinical trials under fasted and fed conditions (ClinicalTrials.gov NCT02184585 and NCT02509104). Both trials were open-label, randomized, single-dose, crossover studies in healthy male adults aged 18-65 years...
August 11, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28789947/impact-of-5%C3%AE-reductase-inhibitors-on-disease-reclassification-among-men-on-active-surveillance-for-localized-prostate-cancer-with-favorable-features
#9
Charles Dai, Vishnu Ganesan, Joseph Zabell, Yaw A Nyame, Nima Almassi, Daniel J Greene, Daniel Hettel, Chad Reichard, Samuel C Haywood, Hans Arora, Anna Zampini, Alice Crane, Jianbo Li, Ahmed Elshafei, Cristina Magi-Galluzzi, Robert J Stein, Khaled Fareed, Michael Gong, J Stephen Jones, Eric A Klein, Andrew J Stephenson
PURPOSE: To determine the effect of 5α-reductase inhibitors (5-ARI) on disease reclassification in men with prostate cancer optimally selected for active surveillance (AS). MATERIALS AND METHODS: A retrospective review identified 635 patients on AS between 2002-2015. Patients with favorable cancer features on repeat biopsy, defined as absence of Gleason upgrading, were included in the cohort. Patients were stratified by those who did or did not receive finasteride/dutasteride within 1 year of diagnosis...
August 5, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28789926/commentary-on-redirecting-abiraterone-metabolism-to-fine-tune-prostate-cancer-anti-androgen-therapy-li-z-alyamani-m-li-j-rogacki-k-abazeed-m-upadhyay-sk-balk-sp-taplin-me-auchus-rj-sharifi-n-nature-2016-may-25-533-7604-547-51
#10
Byron H Lee
Abiraterone blocks androgen synthesis and prolongs survival in patients with castration-resistant prostate cancer, which is otherwise driven by intratumoral androgen synthesis. Abiraterone is metabolized in patients to Δ(4)-abiraterone (D4A), which has even greater antitumour activity and is structurally similar to endogenous steroidal 5α-reductase substrates, such as testosterone. Here, we show that D4A is converted to at least three 5α-reduced and three 5β-reduced metabolites in human serum. The initial 5α-reduced metabolite, 3-keto-5α-abiraterone, is present at higher concentrations than D4A in patients with prostate cancer taking abiraterone, and is an androgen receptor agonist, which promotes prostate cancer progression...
September 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28765837/the-impact-of-finasteride-and-dutasteride-treatments-on-proliferation-apoptosis-androgen-receptor-5%C3%AE-reductase-1-and-5%C3%AE-reductase-2-in-tramp-mouse-prostates
#11
Alexander B Opoku-Acheampong, Jamie N Henningson, Brian L Lindshield
BACKGROUND: Previously, we studied the effect of finasteride- or dutasteride-containing diets in male C57BL/6 TRAMP x FVB mice. Pre (6 weeks of age) and post (12 weeks of age) groups received finasteride or dutasteride to determine the efficacy of these pharmaceuticals on prostate cancer (PCa) development in male C57BL/6 TRAMP x FVB mice. Post-Dutasteride treatment was more effective than Pre-Dutasteride treatment, and dutasteride treatments were more effective than finasteride treatments in decreasing prostatic intraepithelial neoplasia (PIN) progression and PCa development...
July 2017: Heliyon
https://www.readbyqxmd.com/read/28743526/change-in-psa-concentration-in-men-with-psa-2-5-ng-ml-taking-low-dose-finasteride-or-dutasteride-for-male-androgenetic-alopecia
#12
Ho Won Kang, Myeong Heon Chae, Su Hyun Park, Sung Pil Seo, Won Tae Kim, Yong-June Kim, Seok-Joong Yun, Sang-Cheol Lee, Tae Young Yoon, Wun-Jae Kim
PURPOSE: This retrospective cohort study aimed to assess the effect on PSA concentrations of low-dose finasteride or dutasteride treatment for male androgenetic alopecia whose baseline serum PSA < 2.5 ng/mL. PATIENTS AND METHODS: The cohort consisted of 1,379 consecutive male patients who were treated for androgenetic alopecia with finateride 1.25 mg daily or dutasteride 0.5 mg every 3 days in 2002-2012 and underwent PSA measurements at baseline and at least once thereafter...
July 22, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28710320/correction-a-phase-ii-trial-of-abiraterone-combined-with-dutasteride-for-men-with-metastatic-castration-resistant-prostate-cancer
#13
(no author information available yet)
No abstract text is available yet for this article.
July 15, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28704587/effects-of-testosterone-administration-and-its-5-alpha-reduction-on-parenchymal-organ-volumes-in-healthy-young-men-findings-from-a-dose-response-trial
#14
T Gagliano-Jucá, E R Tang, S Bhasin, K M Pencina, S Anderson, H Jara, Z Li, K Melamud, S L Coleman, A Aakil, R R Almeida, G Huang, T G Travison, T W Storer, S Basaria
Animal data shows that testosterone administration increases the volume of some parenchymal organs. However, the effects of exogenous testosterone on solid abdominal organs in humans remain unknown. The present study evaluated the effects of testosterone administration on the volume of liver, spleen and kidneys in a dose-response trial. Young healthy men aged 18-50 years participating in the 5α-Reductase (5aR) Trial. All participants received monthly injections of 7.5 mg leuprolide acetate to suppress endogenous testosterone secretion and weekly injections of 50, 125, 300 or 600 mg of testosterone enanthate, and were randomized to receive either 2...
September 2017: Andrology
https://www.readbyqxmd.com/read/28670847/reclassification-of-prostate-cancer-risk-using-sequentially-identified-snps-results-from-the-reduce-trial
#15
RANDOMIZED CONTROLLED TRIAL
Haitao Chen, Rong Na, Vignesh T Packiam, Carly A Conran, Deke Jiang, Sha Tao, Hongjie Yu, Xiaoling Lin, Wei Meng, S Lilly Zheng, Charles B Brendler, Brian T Helfand, Jianfeng Xu
BACKGROUND: Although the clinical validity of risk-associated single nucleotide polymorphisms (SNPs) for assessment of disease susceptibility has been consistently established, risk reclassification from increasing numbers of implicated risk-associated SNPs raises concern that it is premature for clinical use. Our objective is to assess the degree and impact of risk reclassification with the increasing number of SNPs. METHODS: A total of 3239 patients from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial were included...
August 2017: Prostate
https://www.readbyqxmd.com/read/28656603/a-genetic-variant-near-gata3-implicated-in-inherited-susceptibility-and-etiology-of-benign-prostatic-hyperplasia-bph-and-lower-urinary-tract-symptoms-luts
#16
RANDOMIZED CONTROLLED TRIAL
Rong Na, Brian T Helfand, Haitao Chen, Carly A Conran, Susan E Crawford, Simon W Hayward, Teuvo L J Tammela, Judy Hoffman-Bolton, Siqun L Zheng, Patrick C Walsh, Johanna Schleutker, Elizabeth A Platz, William B Isaacs, Jianfeng Xu
BACKGROUND: Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) are common conditions. Little is known about their etiologies except that studies have suggested a substantial heritable component. Our objective is to provide a comprehensive, genome-wide evaluation of inherited risks and possible mechanisms of etiology in BPH. METHODS: We performed a three-stage, genome-wide association study (GWAS) of men from three independent populations, the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial, the CLUE II cohort, and a Finnish hospital-based population...
August 2017: Prostate
https://www.readbyqxmd.com/read/28650680/transurethral-resection-of-prostate-and-bleeding-a-prospective-randomized-double-blind-placebo-controlled-trial-to-see-the-efficacy-of-short-term-use-of-finasteride-and-dutasteride-on-operative-blood-loss-and-prostatic-microvessel-density
#17
Ankur Bansal, Aditi Arora
OBJECTIVE: The aim of this study was to determine the efficacy of short-duration use of finasteride and dutasteride before transurethral resection of the prostate (TURP) on intraoperative blood loss and microvessel density (MVD) of prostate stroma and suburethral tissues in benign prostatic hyperplasia (BPH). METHODS: This study includes 450 patients who were planned for TURP. They were prospectively randomized into three groups (150 patients each). Group 1 received placebo, group 2 received finasteride, 5 mg per day, and group 3 patients received dutasteride, 0...
September 2017: Journal of Endourology
https://www.readbyqxmd.com/read/28632494/long-term-dutasteride-therapy-in-men-with-benign-prostatic-hyperplasia-alters-glucose-and-lipid-profiles-and-increases-severity-of-erectile-dysfunction
#18
Abdulmaged Traish, Karim Sultan Haider, Gheorghe Doros, Ahmad Haider
Background Dutasteride has been successfully used in treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). However, dutasteride inhibits 5α-reductase type 1 and type 2 enzymes and may compromises glucocorticoids and androgen metabolism and alters metabolic function resulting in undesirable metabolic and sexual adverse side effects. Aim The aim of this study was to investigate the long-term adverse effects of dutasteride therapy in men with BPH on: i) blood glucose, ii) glycated hemoglobin (HbA1c), iii) low density lipoprotein-cholesterol (LDL-C); high density lipoprotein-cholesterol (HDL-C) and total cholesterol (TC), iv) testosterone (T), v) liver alanine and aspartate aminotransferases (ALT and AST) and vi) erectile dysfunction (ED)...
June 21, 2017: Hormone Molecular Biology and Clinical Investigation
https://www.readbyqxmd.com/read/28602645/synthesis-and-comprehensive-structural-and-physicochemical-characterization-of-dutasteride-hydrochloride-hydrate-solvates
#19
Marcin Górecki, Alicja Dziedzic, Roman Luboradzki, Anna Ostaszewska, Jadwiga Frelek, Wojciech J Szczepek
Four crystalline dutasteride hydrochloride hydrate solvates containing respectively methanol, ethanol, acetone and acetonitrile molecules were obtained. All samples were characterized by extensive spectroscopic analysis with infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC) and (1)H as well as (13)C NMR techniques. For three solvates, i.e. methanol, ethanol and acetone solvates, the single crystal X-ray diffraction (SCXRD) experiments were possible, and their respective crystal and molecular structures were determined...
June 9, 2017: Steroids
https://www.readbyqxmd.com/read/28585572/the-combination-of-histological-prostate-atrophy-and-inflammation-is-associated-with-lower-risk-of-prostate-cancer-in-biopsy-specimens
#20
D M Moreira, D M de O Freitas, J C Nickel, G L Andriole, R Castro-Santamaria, S J Freedland
BACKGROUND: To evaluate whether the presence of both prostate atrophy (PA) and chronic prostate inflammation (CPI) in the same biopsy and in the same biopsy core are associated with prostate cancer (PCa) risk and grade in repeat biopsies. METHODS: Retrospective analyses of 6132 men who were 50-75 years old undergoing 2-year repeat prostate biopsy after a negative baseline biopsy for PCa in the REduction by DUtasteride of prostate Cancer Events (REDUCE) study. PA, CPI and PCa were determined by central pathology...
June 6, 2017: Prostate Cancer and Prostatic Diseases
keyword
keyword
43774
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"